DUPIXENT myway®

Enrollment Form

FOR ALLERGISTS

› **Complete the entire form and submit pages 1-3** to *DUPIXENT MyWay®* via fax at **1-844-387-9370** or **Document Drop at www.patientsupportnow.org** (code: 8443879370)

› For assistance, call **1-844-DUPIXEN(T) (1-844-387-4936) Option 1**, Monday–Friday, 8 AM–9 PM ET

PATIENT TO FILL OUT

Section 1. Patient Information

Patient name (first, MI, last) _____

DOB _____ Gender ☐ F ☐ M

Preferred language (if not English) _____

Address _____

City _____ State _____ ZIP _____

Scan to add *DUPIXENT MyWay®* to the contacts list in your smartphone

Mobile phone (_____)_____ ☐ Preferred # ☐ Voicemail

Best time to call ☐ 8–10 AM ☐ 10 AM–12 PM ☐ 12–2 PM ☐ 2–4 PM ☐ 4–6 PM ☐ 6–9 PM

Email _____

Alternate phone (_____)_____ ☐ Preferred # ☐ Voicemail

☐ **I have read the Text Messaging Consent in Section 7 and expressly consent to receive text messages by or on behalf of the Program.**

Patient Authorizations

I have read and agree to the Patient Authorization to Use and Disclose Health Information included in Section 6.

Patient Sign _____ Date

(1 of 2) **Patient signature/Legal representative if patient is <18 years (Puerto Rico <21 years)**

Printed name if signed by legal representative if patient is <18 years

I have read and agree to the Patient Certifications included in Section 7.

Patient Sign _____ Date

(2 of 2) **Patient signature/Legal representative if patient is <18 years (Puerto Rico <21 years)**

Representative relationship to patient if patient is <18 years

PRESCRIBER TO FILL OUT

Section 2. Insurance Information ☐ Patient has no insurance.

Primary Rx insurance name _____

Rx insurance phone (_____) _____

Policy ID # _____ Group # _____

Rx BIN # _____ Rx PCN # _____

Primary medical insurance name _____

Insurance phone (_____) _____

Policy ID # _____ Group # _____

Policyholder name (first/last) _____

Relationship to patient _____

☐ **I have already sent this prescription to the specialty pharmacy.**

By checking the box, I acknowledge *DUPIXENT MyWay* will not conduct a benefits verification. The specialty pharmacy is responsible for securing coverage on my patient's behalf.

My preferred specialty pharmacy is _____ Phone (_____) _____ Fax (_____) _____

Section 3. Prescriber Information

Prescriber name _____

Specialty _____

Address _____

City _____ State _____ ZIP _____

Prescriber NPI # _____

Site/facility name _____

Office contact name _____

Office contact email _____

Phone (_____) _____ Fax (_____) _____

Tax ID # _____

Section 4. Diagnosis (Choose ONE) Date of diagnosis _____/_____/_____

Moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma ☐ **Primary diagnosis**

☐ J45.50 Severe persistent asthma, uncomplicated

☐ J45.40 Moderate persistent asthma, uncomplicated

☐ Oral corticosteroid dependent

☐ Eosinophilic phenotype

Moderate-to-severe atopic dermatitis ☐ **Primary diagnosis**

☐ L20.9 Atopic dermatitis, unspecified ☐ L20.89 Other atopic dermatitis

Chronic rhinosinusitis with nasal polyposis ☐ **Primary diagnosis**

☐ J33.9 Nasal polyps, unspecified ☐ J33.0 Polyp of nasal cavity

Other ICD-10-CM code

☐ _____

ICD-10-CM=*International Classification of Diseases, Tenth Revision, Clinical Modification.*

! **Prescriber to fill out** required prescription information on page 2

Please see accompanying full Prescribing Information or visit DUPIXENThcp.com.

DUPIXENT® (dupilumab) Injection 100mg · 200mg · 300mg

DUPIXENT myway®

Enrollment Form

FOR ALLERGISTS

› **Complete the entire form and submit pages 1-3** to *DUPIXENT MyWay®* via fax at **1-844-387-9370** or **Document Drop at www.patientsupportnow.org** (code: 8443879370)

› For assistance, call **1-844-DUPIXEN(T) (1-844-387-4936) Option 1**, Monday–Friday, 8 AM–9 PM ET

Patient Name _____ **DOB** _____

Prescriber Name _____ **Prescriber Phone #** _____ **NPI #** _____

Prescriber Address _____ **Prescriber State License #** (Required for prescribers in Puerto Rico only) _____

PRESCRIBER TO FILL OUT

Section 5a. DUPIXENT® (dupilumab) Prescription Information

Quick Start may be able to provide DUPIXENT at no cost to help bridge patients to therapy if there is a coverage delay. Fill out sections 5a and 5b completely to determine patient eligibility.

Rx: DUPIXENT® (dupilumab) (100 mg/0.67 mL, 200 mg/1.14 mL, or 300 mg/2 mL)

Prescription: ☐ New start ☐ Sample product provided Date _____/_____/_____ Known drug allergies _____

Device type (Choose ONE): ☐ Pre-filled **syringe** (100/200/300 mg) **OR** ☐ Pre-filled **pen** (200/300 mg) **(for use in indicated patients ≥2 years)**

Quantity sufficient up to 84-day supply for every-2-week dosing (or up to 56-day supply for every-4-week dosing) **Refills** _____

Moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma	**Patients aged ≥12 years**		☐ **Initial loading dose:** 400 mg SIG: 2 (200 mg/1.14 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 200 mg SIG: 1 (200 mg/1.14 mL) injection subcutaneously every 2 weeks, starting on Day 15 **OR** ☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 2 weeks, starting on Day 15
			Dosage for patients with oral corticosteroid-dependent asthma or with co-morbid moderate-to-severe atopic dermatitis or adults with co-morbid chronic rhinosinusitis with nasal polyposis ☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 2 weeks, starting on Day 15
	Patients aged 6-11 years: **Weight: _____ kg** **(1 kg=2.2 lbs)**	**Weight 15 kg to <30 kg**	☐ **Initial and subsequent doses:** 100 mg SIG: 1 (100 mg/0.67 mL) injection subcutaneously every 2 weeks **OR** ☐ **Initial and subsequent doses:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 4 weeks
		Weight ≥30 kg	☐ **Initial and subsequent doses:** 200 mg SIG: 1 (200 mg/1.14 mL) injection subcutaneously every 2 weeks
	Patients aged 6-11 years with asthma **and** comorbid moderate-to-severe atopic dermatitis: **Weight: _____ kg** **(1 kg=2.2 lbs)**	**Weight 15 kg to <30 kg**	☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 4 weeks, starting on Day 29
		Weight 30 kg to <60 kg	☐ **Initial loading dose:** 400 mg SIG: 2 (200 mg/1.14 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 200 mg SIG: 1 (200 mg/1.14 mL) injection subcutaneously every 2 weeks, starting on Day 15
		Weight ≥60 kg	☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 2 weeks, starting on Day 15
Moderate-to-severe atopic dermatitis	**Patients aged ≥18 years**		☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 2 weeks, starting on Day 15
	Patients aged 6-17 years: **Weight: _____ kg** **(1 kg=2.2 lbs)**	**Weight 15 kg to <30 kg**	☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 4 weeks, starting on Day 29
		Weight 30 kg to <60 kg	☐ **Initial loading dose:** 400 mg SIG: 2 (200 mg/1.14 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 200 mg SIG: 1 (200 mg/1.14 mL) injection subcutaneously every 2 weeks, starting on Day 15
		Weight ≥60 kg	☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 2 weeks, starting on Day 15
	Patients aged 6 months–5 years: **Weight: _____ kg** **(1 kg=2.2 lbs)**	**Weight 5 kg to <15 kg**	☐ **Initial and subsequent doses:** 200 mg SIG: 1 (200 mg/1.14 mL) injection subcutaneously every 4 weeks
		Weight 15 kg to <30 kg	☐ **Initial and subsequent doses:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 4 weeks
Chronic rhinosinusitis with nasal polyposis	**Patients aged ≥18 years**		☐ **Initial and subsequent dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 2 weeks

Prescriber Sign

Prescriber signature (No stamps) **Dispense as written** for commercial prescriptions _____ **Date** _____

Prescriber signature (No stamps) **Substitution permitted** _____ **Date** _____

Collaborating MD name _____ (Nurse practitioner/physician assistant) **NPI #** _____

Prescriber Certification: My signature certifies that the person named on this form is my patient; the information provided on this application, to the best of my knowledge, is complete and accurate; that therapy with DUPIXENT is medically necessary; and that I have prescribed DUPIXENT to the patient named on this form for an FDA-approved indication. I understand that my patient's information provided to Regeneron Pharmaceuticals, Inc., Sanofi US, and their affiliates and agents (the "Alliance") is for the use of *DUPIXENT MyWay* solely to verify my patient's insurance coverage; to facilitate the filling of my patient's prescription; to assess, if applicable, my patient's eligibility for patient assistance and other support programs; and to otherwise administer *DUPIXENT MyWay* for the patient. I certify that I have obtained my patient's written authorization in accordance with applicable state and federal law, including the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, to provide the individually identifiable health information on this form to *DUPIXENT MyWay* for these purposes and for the purposes set forth in Section 6 below. Further, I have discussed and confirmed the patient's agreement that they would like to receive the Services and Communications set forth in Section 7 below. If applicable, I authorize *DUPIXENT MyWay* to conduct a benefits investigation for my patient and to act on my behalf for the limited purpose of transmitting this prescription to the appropriate pharmacy designated by the patient per their benefit plan provided that, if this prescription is not so designated, *DUPIXENT MyWay* is authorized to transmit this prescription to a network pharmacy it selects or to the pharmacy otherwise indicated. I understand that any free product distributed through the *DUPIXENT MyWay* Patient Assistance Program is not contingent on any purchase obligations. I also understand that no free product may be submitted for reimbursement to any payer, including Medicare and Medicaid; and no free product may be sold, traded, or distributed for sale. I consent to *DUPIXENT MyWay* contacting me by fax, mail, or email to provide additional information about DUPIXENT injection or *DUPIXENT MyWay*. I understand that *DUPIXENT MyWay* may revise, change, or terminate any program services at any time without notice to me. If I am completing Section 5b, I authorize for my commercially insured patient one or more months of temporary shipments of DUPIXENT during a benefits determination delay or during the appeal process after an initial coverage delay for DUPIXENT by the patient's insurer. I authorize *DUPIXENT MyWay* to forward this prescription to the pharmacy dispensing the DUPIXENT Quick Start Program product to the patient named herein. I agree to assist in efforts to secure access to DUPIXENT for my commercially insured patient in the event of a coverage delay.

If you are a New York prescriber, please use an original New York State prescription form. The prescriber is to comply with his/her state-specific prescription requirements, such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

Please see accompanying full Prescribing Information or visit DUPIXENThcp.com.

DUPIXENT® (dupilumab) Injection
100mg · 200mg · 300mg

DUPIXENT myway®

Enrollment Form

FOR ALLERGISTS

› **Complete the entire form and submit pages 1-3** to *DUPIXENT MyWay®* via fax at **1-844-387-9370** or **Document Drop at www.patientsupportnow.org** (code: 8443879370)

› For assistance, call **1-844-DUPIXEN(T) (1-844-387-4936) Option 1**, Monday–Friday, 8 AM–9 PM ET

Patient Name _____ **DOB** _____

Prescriber Name _____ **Prescriber Phone #** _____ **NPI #** _____

Prescriber Address _____ **Prescriber State License #** (Required for prescribers in Puerto Rico only) _____

PRESCRIBER TO FILL OUT

Section 5b. DUPIXENT® (dupilumab) Quick Start Program Prescription Information (For COMMERCIALLY INSURED patients)

Quick Start may be able to provide DUPIXENT at no cost to help bridge patients to therapy if there is a coverage delay. Fill out sections 5a and 5b completely to determine patient eligibility.

Rx: DUPIXENT® (dupilumab) (100 mg/0.67 mL, 200 mg/1.14 mL, or 300 mg/2 mL)

Prescription: ☐ New start ☐ Sample product provided Date ____/____/____ Known drug allergies _____

Device type (Choose ONE): ☐ Pre-filled **syringe** (100/200/300 mg) **OR** ☐ Pre-filled **pen** (200/300 mg) **(for use in indicated patients ≥2 years)**

Quantity sufficient up to 28–day supply **Refills** _____

Moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma	**Patients aged ≥12 years**		☐ **Initial loading dose:** 400 mg SIG: 2 (200 mg/1.14 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 200 mg SIG: 1 (200 mg/1.14 mL) injection subcutaneously every 2 weeks, starting on Day 15 **OR** ☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 2 weeks, starting on Day 15
			Dosage for patients with oral corticosteroid-dependent asthma or with co-morbid moderate-to-severe atopic dermatitis or adults with co-morbid chronic rhinosinusitis with nasal polyposis ☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 2 weeks, starting on Day 15
	Patients aged 6-11 years: **Weight: _____ kg** **(1 kg=2.2 lbs)**	**Weight 15 kg to <30 kg**	☐ **Initial and subsequent doses:** 100 mg SIG: 1 (100 mg/0.67 mL) injection subcutaneously every 2 weeks **OR** ☐ **Initial and subsequent doses:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 4 weeks
		Weight ≥30 kg	☐ **Initial and subsequent doses:** 200 mg SIG: 1 (200 mg/1.14 mL) injection subcutaneously every 2 weeks
	Patients aged 6-11 years with asthma **and** comorbid moderate-to-severe atopic dermatitis: **Weight: _____ kg** **(1 kg=2.2 lbs)**	**Weight 15 kg to <30 kg**	☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 4 weeks, starting on Day 29
		Weight 30 kg to <60 kg	☐ **Initial loading dose:** 400 mg SIG: 2 (200 mg/1.14 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 200 mg SIG: 1 (200 mg/1.14 mL) injection subcutaneously every 2 weeks, starting on Day 15
		Weight ≥60 kg	☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 2 weeks, starting on Day 15
Moderate-to-severe atopic dermatitis	**Patients aged ≥18 years**		☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 2 weeks, starting on Day 15
	Patients aged 6-17 years: **Weight: _____ kg** **(1 kg=2.2 lbs)**	**Weight 15 kg to <30 kg**	☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 4 weeks, starting on Day 29
		Weight 30 kg to <60 kg	☐ **Initial loading dose:** 400 mg SIG: 2 (200 mg/1.14 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 200 mg SIG: 1 (200 mg/1.14 mL) injection subcutaneously every 2 weeks, starting on Day 15
		Weight ≥60 kg	☐ **Initial loading dose:** 600 mg SIG: 2 (300 mg/2 mL) injections subcutaneously on Day 1 ☐ **Subsequent (maintenance) dose:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 2 weeks, starting on Day 15
	Patients aged 6 months–5 years: **Weight: _____ kg** **(1 kg=2.2 lbs)**	**Weight 5 kg to <15 kg**	☐ **Initial and subsequent doses:** 200 mg SIG: 1 (200 mg/1.14 mL) injection subcutaneously every 4 weeks
		Weight 15 kg to <30 kg	☐ **Initial and subsequent doses:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 4 weeks
Chronic rhinosinusitis with nasal polyposis	**Patients aged ≥18 years**		☐ **Initial and subsequent doses:** 300 mg SIG: 1 (300 mg/2 mL) injection subcutaneously every 2 weeks

Prescriber Sign

Prescriber signature (No stamps) **Dispense as written** for Quick Start prescriptions (Prescriber must fill out and sign both prescriptions in sections 5a and 5b) **Date**

Prescriber signature (No stamps) **Substitution permitted** **Date**

Collaborating MD name_____ (Nurse practitioner/physician assistant) **NPI #**_____

Prescriber Certification: My signature certifies that the person named on this form is my patient; the information provided on this application, to the best of my knowledge, is complete and accurate; that therapy with DUPIXENT is medically necessary; and that I have prescribed DUPIXENT to the patient named on this form for an FDA-approved indication. I understand that my patient's information provided to Regeneron Pharmaceuticals, Inc., Sanofi US, and their affiliates and agents (the "Alliance") is for the use of *DUPIXENT MyWay* solely to verify my patient's insurance coverage; to facilitate the filling of my patient's prescription; to assess, if applicable, my patient's eligibility for patient assistance and other support programs; and to otherwise administer *DUPIXENT MyWay* for the patient. I certify that I have obtained my patient's written authorization in accordance with applicable state and federal law, including the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, to provide the individually identifiable health information on this form to *DUPIXENT MyWay* for these purposes and for the purposes set forth in Section 6 below. Further, I have discussed and confirmed the patient's agreement that they would like to receive the Services and Communications set forth in Section 7 below. If applicable, I authorize *DUPIXENT MyWay* to conduct a benefits investigation for my patient and to act on my behalf for the limited purpose of transmitting this prescription to the appropriate pharmacy designated by the patient per their benefit plan provided that, if this prescription is not so designated, *DUPIXENT MyWay* is authorized to transmit this prescription to a network pharmacy it selects or to the pharmacy otherwise indicated. I understand that any free product distributed through the *DUPIXENT MyWay* Patient Assistance Program is not contingent on any purchase obligations. I also understand that no free product may be submitted for reimbursement to any payer, including Medicare and Medicaid; and no free product may be sold, traded, or distributed for sale. I consent to *DUPIXENT MyWay* contacting me by fax, mail, or email to provide additional information about DUPIXENT injection or *DUPIXENT MyWay*. I understand that *DUPIXENT MyWay* may revise, change, or terminate any program services at any time without notice to me. If I am completing Section 5b, I authorize for my commercially insured patient one or more months of temporary shipments of DUPIXENT during a benefits determination delay or during the appeal process after an initial coverage delay for DUPIXENT by the patient's insurer. I authorize *DUPIXENT MyWay* to forward this prescription to the pharmacy dispensing the DUPIXENT Quick Start Program product to the patient named herein. I agree to assist in efforts to secure access to DUPIXENT for my commercially insured patient in the event of a coverage delay.

If you are a New York prescriber, please use an original New York State prescription form. The prescriber is to comply with his/her state-specific prescription requirements, such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

Please see accompanying full Prescribing Information or visit DUPIXENThcp.com.

DUPIXENT® (dupilumab) Injection 100mg · 200mg · 300mg

Section 6. Authorization to Use and Disclose Health Information

***Patient:* Please read the following carefully, then date and sign where indicated in *Section 1* on page 1**

I authorize my healthcare providers and staff (together, "Healthcare Providers"), my health insurer, health plan or programs that provide me healthcare benefits (together, "Health Insurers"), and any specialty pharmacies ("Specialty Pharmacies") that dispense my medication to disclose to Regeneron Pharmaceuticals, Inc., Sanofi US, and their affiliates and agents (together, the "Alliance") health information about me, including information related to my medical condition and treatment, health insurance coverage and claims, and prescription (including fill/refill information) related to my prescription for DUPIXENT® (dupilumab) therapy ("My Information"). I understand the disclosure to the Alliance will be for the purposes of enrolling me in, and providing certain services through the "*DUPIXENT MyWay* Program," including:

- to determine if I am eligible to participate in *DUPIXENT MyWay* coverage assistance programs, patient assistance programs, or other support programs
- to investigate my health insurance coverage for DUPIXENT injection
- to obtain prior authorization for coverage
- to assist with appeals of denied claims for coverage
- for the operation and administration of the *DUPIXENT MyWay* Program
- to refer me to, or to determine my eligibility for, other programs, or alternative sources of funding or coverage that may be available to provide assistance to me with the costs of my medication
  - I understand that the Alliance may de-identify My Information and use it in performing research, education, business analytics, marketing studies, or for other commercial purposes, including linkage with other de-identified information the Alliance receives from other sources. I understand that members of the Alliance may share My Information, including identifiable health information, among themselves in order to de-identify it for these purposes and as needed to perform the Services or to communicate with me by mail, telephone, or email, or, if I indicate my agreement and consent in Section 1 on page 1, by text. I understand and agree that the Alliance may use My Information for these purposes and may share My Information with my Healthcare Providers, Health Insurers and Specialty Pharmacies.
  - I understand and agree that my Healthcare Providers, Health Insurers, and Specialty Pharmacies may receive remuneration from the Alliance in exchange for disclosing My Information to the Alliance and/or for providing me with support services in connection with the *DUPIXENT MyWay* Program.

Once My Information has been disclosed to the Alliance, I understand that federal privacy laws may no longer protect it from further disclosure. However, I also understand the Alliance has agreed to protect My Information by using and disclosing it only for the purposes allowed by me in this Authorization or as otherwise required by law.

I understand that I do not have to sign this Authorization. A decision by me not to sign this Authorization will not affect my ability to obtain medical treatment, payment for treatment, insurance coverage, access to health benefits or Alliance medications from covered entities such as Health Care Providers, Health Insurers, and Specialty Pharmacies. However, if I do not sign this Authorization, I understand that I will not be able to participate in the *DUPIXENT MyWay* Program.

I understand that this Authorization expires 18 months from the date support is last provided under the Program, or until my local state law requires expiration, subject to applicable law, unless and until I withdraw (take back) this Authorization before then, or as otherwise required by law. Further, I understand that I may withdraw this Authorization at any time by mailing or faxing a written request to *DUPIXENT MyWay* at PO Box 220128, Charlotte, NC 28222; Fax: 1-844-387-9370. Withdrawal of this Authorization will end my participation in the *DUPIXENT MyWay* Program and will not affect any disclosure of My Information based on this Authorization made before my request is received and processed by my Healthcare Providers, Health Insurers, and Specialty Pharmacies.

I understand that I may request a copy of this Authorization.

Section 7. Patient Certifications

***Patient:* Please read the following carefully, then date and sign where indicated in *Section 1* on page 1**

I am enrolling in the *DUPIXENT MyWay* Program (the "Program") and authorize Regeneron Pharmaceuticals, Inc., Sanofi US, and their affiliates and agents (together the "Alliance") to provide me services under the Program, as described in the Program Enrollment Form and as may be added in the future. Such services include medication and adherence communications and support, medication dispensing support, coverage and financial assistance support, disease and medication education, injection training, and other support services (the "Services").

If enrolling in the *DUPIXENT MyWay* Copay Card Program, I understand that Copay Card information will be sent to my designated specialty pharmacy along with my prescription, and any assistance with my applicable cost-sharing or copayment for DUPIXENT® (dupilumab) injection will be made in accordance with the Program terms and conditions.

I authorize the "Alliance" to verify my eligibility for the *DUPIXENT MyWay* Patient Assistance Program, and I understand that such verification may include contacting me or my healthcare provider for additional information and/or reviewing additional financial, insurance, and/or medical information. I authorize the Alliance under the Fair Credit Reporting Act to use my demographic information to access reports on my individual credit history from consumer reporting agencies. I understand that, upon request, the Alliance will tell me whether an individual consumer report was requested and the name and address of the agency that furnished it. I further understand and authorize the Alliance to use any consumer reports about me and information collected from me, along with other information they obtain from public and other sources, to estimate my income in conjunction with the Patient Assistance Program eligibility determination process, if applicable. I further understand that no free product may be submitted for reimbursement to any payer, including Medicare and Medicaid; and no free product may be sold, traded, or distributed for sale. If approved for the *DUPIXENT MyWay* Patient Assistance Program, I will not seek to have the value of any medication provided to me under this program counted toward my true-out-of-pocket (TrOOP) cost for prescription drugs for my Medicare Part D Plan. Continuation in the *DUPIXENT MyWay* Patient Assistance Program is conditioned upon timely verification of income. In addition, I agree to notify *DUPIXENT MyWay* if my insurance situation changes.

I authorize the Alliance to contact me by mail, telephone, or email, or, if I indicate my agreement and consent on page 1, by text,* with information about the Program, disease state and products, promotions, services, and research studies, and to ask my opinion about such information and topics, including market research and disease-related surveys (together, the "Communications"). I understand that I may be contacted by the Alliance in the event that I report an adverse event. I understand that I do not have to enroll in the Program or receive the Communications, and that I can still receive DUPIXENT injection, as prescribed by my Healthcare Provider. I may opt out of receiving Communications, individual support services offered by the Program, including the *DUPIXENT MyWay* Copay Card, or opt out of the Program entirely at any time by notifying a Program representative by telephone at 1-844-387-4936 or by sending a letter to *DUPIXENT MyWay*, PO Box 220128, Charlotte, NC 28222. I also understand that the Services may be revised, changed, or terminated at any time.

I understand that my health information, contact information, and other information I, my healthcare provider, and others share with Regeneron Pharmaceuticals, Inc., Sanofi US, and their affiliates and agents (together the "Alliance") is collected to provide me with the assistance I request and for other business purposes of the Alliance, as described in their privacy policy, which is available at regeneron.com/privacy-policy. Depending on where I live, I may have certain rights with respect to my privacy information, including the request to access or delete my personal information. I am aware that Regeneron may not be required to fulfill my requests in certain circumstances. I understand that to exercise these rights, I may contact the Privacy Office by emailing dataprotection@regeneron.com or by calling 844-835-4137. I may reference Sanofi's Global Privacy Policy at sanofi.com/our-responsibility/sanofi-global-privacy-policy for further information regarding these rights with respect to Sanofi US.

Text Messaging Consent:

*I acknowledge that by checking the Text Messaging Consent box on page 1, I expressly consent to receive text messages from or on behalf of the Program at the mobile telephone number(s) that I provide.

I confirm that I am the subscriber for the mobile telephone number(s) provided, and I agree to notify the Alliance promptly if any of my number(s) change in the future. I understand that my wireless service provider's message and data rates may apply. I understand that I can opt out of future text messages at any time by texting SMSSTOP to 39771 and 69929 from my mobile phone, and that I can get help for text messages by texting SMSHELP to 39771 and 69929. I also understand that additional text messaging terms and conditions may be provided to me in the future as part of an opt-in confirmation text message. Message and data rates may apply.

I understand that my consent is not required as a condition of purchasing any goods or services from Regeneron Pharmaceuticals, Inc., Sanofi US, or their affiliates.

You may keep a copy of this form for your records.